Gout drug tapering trial: could patients finally take less medicine?

NCT ID NCT06622603

Recruiting now Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether people with well-controlled gout (for at least 5 years) can safely reduce or stop their daily febuxostat. Fifty-nine adults will be split into three groups: one that lowers the dose, one that stops for 6 months then restarts a lower dose, and one that stays on their usual treatment. Researchers will track uric acid levels and any symptom return over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: febuxostat
What this could lead to: If successful, this could show that some gout patients can safely lower their medication dose without flare-ups, simplifying long-term management.
What could go wrong: This is a small, early-phase trial with only 59 participants. Results may not apply to all gout patients, and reducing medication could still cause symptom return or high uric acid levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GOUT URIC ACID

Contacts and locations

Locations

Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, Gyeonggi-do, 463-707, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.